Medrogestone: Difference between revisions

	WikiDoc Resources for Medrogestone
Articles
Most recent articles on Medrogestone Most cited articles on Medrogestone Review articles on Medrogestone Articles on Medrogestone in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Medrogestone Images of Medrogestone Photos of Medrogestone Podcasts & MP3s on Medrogestone Videos on Medrogestone
Evidence Based Medicine
Cochrane Collaboration on Medrogestone Bandolier on Medrogestone TRIP on Medrogestone
Clinical Trials
Ongoing Trials on Medrogestone at Clinical Trials.gov Trial results on Medrogestone Clinical Trials on Medrogestone at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Medrogestone NICE Guidance on Medrogestone NHS PRODIGY Guidance FDA on Medrogestone CDC on Medrogestone
Books
Books on Medrogestone
News
Medrogestone in the news Be alerted to news on Medrogestone News trends on Medrogestone
Commentary
Blogs on Medrogestone
Definitions
Definitions of Medrogestone
Patient Resources / Community
Patient resources on Medrogestone Discussion groups on Medrogestone Patient Handouts on Medrogestone Directions to Hospitals Treating Medrogestone Risk calculators and risk factors for Medrogestone
Healthcare Provider Resources
Symptoms of Medrogestone Causes & Risk Factors for Medrogestone Diagnostic studies for Medrogestone Treatment of Medrogestone
Continuing Medical Education (CME)
CME Programs on Medrogestone
International
Medrogestone en Espanol Medrogestone en Francais
Business
Medrogestone in the Marketplace Patents on Medrogestone
Experimental / Informatics
List of terms related to Medrogestone

Medrogestone
Clinical data
Pregnancy; category	X;
Routes of; administration	Oral
ATC code	G03DB03 (WHO) ; G03FB07 (WHO) (with estrogen);
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	100%
Metabolism	Hydroxylation and glucuronidation
Elimination half-life	4 to 5 hours
Excretion	Renal and fecal, as metabolites
Identifiers
	IUPAC name 6,17-dimethylpregna-4,6-diene-3,20-dione;
CAS Number	977-79-7;
PubChem CID	9949848;
ChemSpider	8125459;
UNII	077DN93G5B;
KEGG	D04885;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C23H32O2
Molar mass	340.5 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=C4\C=C3\C(=C/[C@@H]1[C@H](CC[C@@]2([C@@](C(=O)C)(CC[C@@H]12)C)C)[C@@]3(C)CC4)C;

VisualWikitext

Latest revision as of 16:39, 20 August 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medrogestone (INN; trade names Colpro(ne) by Wyeth and Prothil by Solvay) is a progestin, a synthetic drug with similar effects as progesterone, a hormone involved in the menstrual cycle and pregnancy. As of 2010, it is no longer available in Germany or Austria.

Indications

In the past, medrogestone was used in the treatment of endometrial cancer and in some regimens for breast cancer, and, in men, for benign prostatic hyperplasia. It still finds use in the treatment of amenorrhea and as the progestin component in certain forms of menopausal hormone replacement therapy.

Contraindications

Intrahepatic cholestasis of pregnancy (acute or in history), vaginal bleeding of unknown origin, and severe diseases of the liver such as tumours are absolute contraindications for medrogestone. Relative contraindications include a history of jaundice or itching in pregnancy or gestational pemphigoid.

Pregnancy and lactation

Medrogestone is contraindicated during pregnancy because progestogens are associated with risks for the foetus in animals and humans. Studies in pregnant rabbits have shown skeletal deformations under 3 mg medrogestone per kilogram body weight but not under 1 mg/kg. Typical therapeutic doses are between 0.1 and 0.25 mg/kg.

It is not known whether medrogestone passes into breast milk, but it is to be expected given its lipophilicity and studies with chemically related progestins.

Adverse effects

Medrogestone seldom produces adverse effects, all of which are typical of progestogens. They include lack of appetite, nausea, headache, dizziness, and depression.

Overdose

The acute toxicity of the drug is low. Overdose causes only harmless side-effects such as nausea and vaginal bleeding. The Template:LD50 has been found to range between 500 mg/kg in dogs and over 3000 mg/kg in rats. Chronic toxicity has been examined in animals, but nothing but the typical adverse effects of progestogens, and reduction of prostatic weight in Rhesus Monkeys, have been found. Accidental intake of the drug, including in children, is not dangerous.

Chemical properties

Medrogestone is a steroid. More specifically, it is a derivative of pregna-4,6-diene structurally related to the progestin chlormadinone acetate and the antiandrogen cyproterone acetate. As is frequently found in other synthetic steroid hormones, medrogestone possesses a lipophilic group at position 6. However in contrast to chlormadinone acetate and cyproterone acetate or to fluocinolone that contain a chlorine or fluorine respectively at position 6, medrogestone contains a methyl substituent at this position. The methyl in position 17 is unusual for a steroid, as many such drugs carry an oxygen atom in that position.

Pharmacology

Pharmacokinetics

The drug is absorbed quickly and completely from the gut and reaches peak plasma concentrations after about one to four hours. Unlike many other steroids it binds neither to transcortin (corticosteroid-binding globulin, CBG, which binds progesterone nor to sex hormone-binding globulin (SHBG), but to albumin.Medrogestone itself cannot be excreted. The substance is hydroxylised and glucuronidised in the liver, and the resulting metabolites are eliminated via urine and faeces.

Pharmacodynamics

The profile of medrogestone is similar to the natural hormone progesterone. It has pronounced progestogenic effects and opposes the proliferative effects of estrogen in the utereus, but lacks anabolic, androgenic, estrogenic and corticoid activity. In extremely high doses it is an androgen antagonist (in 2500-fold therapeutic doses) as well as an antigonadotropin.

Interactions

Enzyme inducers such as barbiturates, phenylbutazone, phenytoin, ampicillin or tetracyclines are expected to reduce plasma concentrations of medrogestone, but no systematic research has been done.

@@ Line 45: / Line 45: @@
 ==Overview==
-'''Medrogestone''' ([[International Nonproprietary Name|INN]]; trade names '''Colpro(ne)''' by [[Wyeth]] and '''Prothil''' by [[Solvay (company)|Solvay]]) is a [[progestin]], a synthetic [[pharmaceutical drug|drug]] with similar effects as [[progesterone]],<ref name="ODDB" /> a hormone involved in the [[menstrual cycle]] and [[pregnancy]]. As of 2010, it is no longer available in Germany or Austria.<ref name="Austria-Codex" />
+'''Medrogestone''' ([[International Nonproprietary Name|INN]]; trade names '''Colpro(ne)''' by [[Wyeth]] and '''Prothil''' by [[Solvay (company)|Solvay]]) is a [[progestin]], a synthetic [[pharmaceutical drug|drug]] with similar effects as [[progesterone]], a hormone involved in the [[menstrual cycle]] and [[pregnancy]]. As of 2010, it is no longer available in Germany or Austria.
 ==Indications==
-In the past, medrogestone was used in the treatment of [[endometrial cancer]] and in some regimens for [[breast cancer]], and, in men, for [[benign prostatic hyperplasia]]. It still finds use in the treatment of [[amenorrhea]] and as the progestin component in certain forms of [[Hormone replacement therapy (menopause)|menopausal hormone replacement therapy]].<ref name="Martindale" />
+In the past, medrogestone was used in the treatment of [[endometrial cancer]] and in some regimens for [[breast cancer]], and, in men, for [[benign prostatic hyperplasia]]. It still finds use in the treatment of [[amenorrhea]] and as the progestin component in certain forms of [[Hormone replacement therapy (menopause)|menopausal hormone replacement therapy]].
 ==Contraindications==
-[[Intrahepatic cholestasis of pregnancy]] (acute or in history), [[vaginal bleeding]] of unknown origin, and severe diseases of the liver such as tumours are absolute contraindications for medrogestone. Relative contraindications include a history of [[jaundice]] or [[itch]]ing in pregnancy or [[gestational pemphigoid]].<ref name="Daunderer" />
+[[Intrahepatic cholestasis of pregnancy]] (acute or in history), [[vaginal bleeding]] of unknown origin, and severe diseases of the liver such as tumours are absolute contraindications for medrogestone. Relative contraindications include a history of [[jaundice]] or [[itch]]ing in pregnancy or [[gestational pemphigoid]].
 ===Pregnancy and lactation===
-Medrogestone is contraindicated during pregnancy because progestogens are associated with risks for the foetus in animals and humans.<ref name="ODDB" /> Studies in pregnant rabbits have shown [[skeletal]] deformations under 3&nbsp;mg medrogestone per kilogram body weight but not under 1&nbsp;mg/kg.<ref name="Daunderer" /> Typical therapeutic doses are between 0.1 and 0.25&nbsp;mg/kg.
+Medrogestone is contraindicated during pregnancy because progestogens are associated with risks for the foetus in animals and humans. Studies in pregnant rabbits have shown [[skeletal]] deformations under 3&nbsp;mg medrogestone per kilogram body weight but not under 1&nbsp;mg/kg. Typical therapeutic doses are between 0.1 and 0.25&nbsp;mg/kg.
 It is not known whether medrogestone passes into [[breast milk]], but it is to be expected given its [[lipophilicity]] and studies with chemically related progestins.